Zimmer Biomet Reports Q3 Sales, Raises Full-Year Guidance
Zimmer Biomet reported third-quarter net sales of $2.063 billion, up 3.1% reported and 3.7% at constant currency. GAAP diluted EPS fell 13.8% to $1.00, while adjusted diluted EPS was $1.90, unchanged year over year. The company raised full-year organic constant-currency sales growth and adjusted EPS guidance.
Zimmer Biomet Holdings, Inc. announced its financial results for the third quarter ended September 30, 2026, reporting net sales of $2.063 billion, a 3.1% increase on a reported basis and 3.7% on a constant currency basis. The company reported GAAP diluted earnings per share of $1.00, a 13.8% decrease from the prior year, while adjusted diluted earnings per share were $1.90, consistent with the same period last year. Management highlighted strong performance in its Hips, S.E.T., Technology & Data, Bone Cement, and Surgical franchises, which collectively represent two-thirds of the company's business.
Based on this performance, the company raised its full-year organic constant-currency sales growth and adjusted EPS guidance. The company also generated $560.0 million in operating cash flow and $372.4 million in free cash flow during the quarter.